Co-Diagnostics' India JV Secures CDSCO License for PCR Instrument

Event summary

  • CoSara Diagnostics, a joint venture between Co-Diagnostics and ASE Group, received a CDSCO license on Form MD-5 to manufacture and sell the CoSara PCR Pro™ instrument in India.
  • The license authorizes production at CoSara's Ranoli, India facility, marking the final regulatory hurdle before commercialization.
  • CoSara PCR test kits for Mycobacterium tuberculosis (MTB) and human papillomavirus (HPV) require separate regulatory clearance before sale.
  • The CoSara PCR Pro is a localized version of Co-Diagnostics' PCR Pro point-of-care instrument, designed for decentralized PCR testing.

The big picture

This regulatory milestone strengthens Co-Diagnostics' strategy of localizing its PCR technology through joint ventures, addressing demand for affordable, high-quality diagnostics in emerging markets. The CDSCO license positions CoSara to compete in India's growing point-of-care diagnostics sector, where decentralized testing is increasingly critical for infectious disease management. The partnership with ASE Group, a longstanding Indian manufacturing institution, underscores the importance of local production in navigating regulatory and logistical challenges.

What we're watching

Regulatory Momentum
Whether the CDSCO license will accelerate approval for CoSara's PCR test kits, enabling full commercialization.
Market Penetration
The pace at which CoSara can establish the PCR Pro in India's decentralized diagnostics market.
Strategic Alignment
How Co-Diagnostics leverages this joint venture to expand its global footprint in underserved regions.

Related topics

Diagnostics